Interchange Capital Partners LLC acquired a new stake in Semler Scientific Inc. (NASDAQ:SMLR - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,284,575 shares of the company's stock, valued at approximately $46,502,000. Semler Scientific makes up 13.0% of Interchange Capital Partners LLC's portfolio, making the stock its biggest holding. Interchange Capital Partners LLC owned 13.39% of Semler Scientific at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in Semler Scientific in the fourth quarter worth $30,000. Jones Financial Companies Lllp bought a new stake in Semler Scientific in the 4th quarter valued at about $34,000. Larson Financial Group LLC bought a new position in Semler Scientific in the fourth quarter worth approximately $38,000. NewEdge Advisors LLC raised its holdings in Semler Scientific by 318.3% during the fourth quarter. NewEdge Advisors LLC now owns 732 shares of the company's stock worth $40,000 after buying an additional 557 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Semler Scientific by 65.4% during the fourth quarter. Legal & General Group Plc now owns 2,056 shares of the company's stock valued at $111,000 after buying an additional 813 shares during the last quarter. Institutional investors own 49.37% of the company's stock.
Semler Scientific Stock Up 8.6%
Shares of NASDAQ:SMLR traded up $3.65 during mid-day trading on Thursday, hitting $45.97. 1,501,479 shares of the company traded hands, compared to its average volume of 564,914. The stock has a market cap of $512.66 million, a P/E ratio of -17.61 and a beta of 1.39. The company has a current ratio of 0.52, a quick ratio of 0.51 and a debt-to-equity ratio of 0.59. Semler Scientific Inc. has a 12-month low of $21.77 and a 12-month high of $81.56. The stock has a 50-day moving average price of $37.03 and a two-hundred day moving average price of $42.35.
Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter. Semler Scientific had a negative net margin of 60.69% and a positive return on equity of 19.75%. The company had revenue of $8.84 million for the quarter.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Semler Scientific from a "buy" rating to a "sell" rating in a research report on Thursday, May 22nd. Maxim Group raised Semler Scientific to a "strong-buy" rating and set a $95.00 price objective for the company in a report on Wednesday. Finally, Benchmark initiated coverage on Semler Scientific in a research note on Tuesday. They issued a "buy" rating and a $101.00 price objective for the company.
Get Our Latest Stock Analysis on SMLR
About Semler Scientific
(
Free Report)
Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.
See Also

Before you consider Semler Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semler Scientific wasn't on the list.
While Semler Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.